United StatesBreaking News

Nurix Therapeutics (NASDAQ:NRIX) announced on June 8, 2026, that it has entered into a global licensing and collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg (NX-5948).

HSBC Chief Executive Officer Georges Elhedery says that while certain roles will be displaced by artificial intelligence, the productivity gains can be reinvested. "I would like to be able to accelerate and bring forward a lot of the ambitious deliverables we have for the future," Elhedery tells Bloomberg's Francine Lacqua. "That requires investment, and that is job creation."

Global oil markets faced heightened volatility on Monday as investors reacted to an escalation in regional conflict.

Anna Edwards, Lizzy Burden and Mark Cudmore break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade."

Founders Forum Group CEO Carolyn Dawson speaks to Bloomberg's Tom Mackenzie to kick off a big week of tech events in London. She joined Bloomberg Daybreak Europe.

Intesa Sanpaolo offered to buy Banca Monte dei Paschi di Siena for 30.6 billion ($35.3 billion). The Milan-based bank will offer 1.6 of its own shares and 1 in cash for each Monte Paschi share. The bid comes the day after Banco BPM pitched its own merger with Monte Paschi, considered to be the world's oldest bank. Bloomberg's Manuel Baigorri reports.

Sally Wan, CEO of AXA Global Private and AXA Greater China, discusses the outlook for the insurance firm's new platform launched at helping high-net-worth and ultra-high-net-worth clients manage their wealth, and look for investment opportunities. She speaks exclusively with Haidi Stroud Watts on "Bloomberg: The Asia Trade".

Asian stocks dropped Monday as AI-related shares sold off after a blistering rally, led by losses in Korean chipmakers SK Hynix and Samsung. Joe Weisenthal and Tracy Alloway from Bloomberg's Odd Lots podcast join Yvonne Man and Stephen Engle on The China Show.

Artiva Biotherapeutics (NASDAQ:ARTV) has shared encouraging clinical findings for its lead therapeutic candidate, AlloNK® (AB-101), during the European Alliance of Associations for Rheumatology (EULAR) 2026 congress.

Seaport Therapeutics (NASDAQ:SPTX) announced today positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial for GlyphAgo™ (SPT-320).

Aclarion (NASDAQ:ACON) announced that its Board of Directors has unanimously rejected an unsolicited, non-binding proposal from Echo Lake Capital to acquire the company at a price of $4 per share.

South Korean stocks plunged as investors pulled back from artificial intelligence bets. Meanwhile, a tech-centered camaraderie was on display last week with Nvidia CEO Jensen Huang's night out in Seoul with South Korea's tech corporate royalty, including leaders from SK Group, LG Group and Naver Corp.